Tol Purewal appointed as head of pulmonary product development at developer of innovative drug delivery technologies for the pharmaceutical industry
Bespak, a developer of innovative drug delivery technologies for the pharmaceutical industry, has announced that it has appointed a new head of pulmonary product development.
Tol Purewal - who joins Bespak from 3M - has been employed by the company to continue its work in the development of pulmonary drug delivery systems that set new and improved standards for orally inhaled therapies.
His primary focus will be to work with the company's existing R and D team to develop cutting-edge drug delivery solutions and offer pharmaceutical partners a range of integrated services including the evaluation of potential drug candidates for inhalation product development.
Purewal, who will be based at Bespak's Milton Keynes site in the UK, will oversee product development from concept and creation and through manufacturing life.
He will also take the lead in extending the company's laboratory capabilities to develop finished medicinal dosage forms for administration to and via the respiratory tract.
"Tol has specialised in the development of inhalation technologies and products for the last 25 years," said Martin Wardhaugh, group director of Bespak's pulmonary business.
"His appointment strengthens the company's existing capabilities and reflects our continued development as providers of drug delivery systems to the pharmaceutical industry." "For more than thirty years, Bespak has been developing a comprehensive world-class portfolio of drug delivery technologies," said Tol Purewal. "I am delighted to be joining a company that has a clear strategic vision for the future and am looking forward to building on the company's strong science and technology base of drug delivery systems for the effective administration of therapeutics to the human respiratory tract."
